N-(5-(dipropylamino)-2-mercapto-1H-benzo[d]imidazol-6-yl)furan-2-carboxamide | 1341236-59-6

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: N-(5-(dipropylamino)-2-mercapto-1H-benzo[d]imidazol-6-yl)furan-2-carboxamide
• CAS: 1341236-59-6
• 化学式: C₁₈H₂₂N₄O₂S
• 分子量: 358.464
• InChiKey: CTDSLVOWSQSPCX-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.32
• 重原子数：
  25.0
• 可旋转键数：
  7.0
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  74.16
• 氢给体数：
  3.0
• 氢受体数：
  5.0

反应信息

• 作为反应物：
  描述：

  N-(5-(dipropylamino)-2-mercapto-1H-benzo[d]imidazol-6-yl)furan-2-carboxamide 在 potassium carbonate 、 potassium hydrogencarbonate 、 间氯过氧苯甲酸 、 potassium iodide 作用下， 以 乙醇 、 二氯甲烷 、 丙酮 为溶剂， 反应 4.25h， 生成 2-[(3,5-dimethyl-4-methoxypyridin-2-yl)methyl]sulfinyl-6-[(2-furanyl)carboxamido]-5-dipropylamino-1H-benzimidazole
  参考文献：
  名称：

  A reverse method for diversity introduction of benzimidazole to synthesize H+/K+-ATP enzyme inhibitors

  摘要：

  A series of 2-[(2-pyridylmethyl)sulfinyl]benzimidazole derivatives were synthesized via a solution phase synthetic route using a reversal method of diversity introduction. Using this synthetic strategy, we obtained two key intermediates (4-A and 4-B) simultaneously, which allows us to introduce diversity points onto the benzimidazole part of the final product under reliable reaction conditions to identify potent H+/K+-ATP enzyme inhibitors. Compound 141 (IC50 = 1.6 x 10 (5) M) was comparable with H+/K+-ATP enzyme inhibitor in vitro. (C) 2011 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2011.05.080
• 作为产物：
  描述：

  在 palladium 10% on activated carbon 、 甲酸铵 、 三乙胺 作用下， 以 四氢呋喃 、 乙醇 为溶剂， 反应 4.0h， 生成 N-(5-(dipropylamino)-2-mercapto-1H-benzo[d]imidazol-6-yl)furan-2-carboxamide
  参考文献：
  名称：

  A reverse method for diversity introduction of benzimidazole to synthesize H+/K+-ATP enzyme inhibitors

  摘要：

  A series of 2-[(2-pyridylmethyl)sulfinyl]benzimidazole derivatives were synthesized via a solution phase synthetic route using a reversal method of diversity introduction. Using this synthetic strategy, we obtained two key intermediates (4-A and 4-B) simultaneously, which allows us to introduce diversity points onto the benzimidazole part of the final product under reliable reaction conditions to identify potent H+/K+-ATP enzyme inhibitors. Compound 141 (IC50 = 1.6 x 10 (5) M) was comparable with H+/K+-ATP enzyme inhibitor in vitro. (C) 2011 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2011.05.080